Clinical Trial Update: Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

View source ↗

Summary

Expanded-access use of Derazantinib for advanced intrahepatic cholangiocarcinoma with FGFR alterations. The program, sponsored by Basilea Pharmaceutica, is no l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Derazantinib (derazantinib)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Intrahepatic Cholangiocarcinoma | Status: NO_LONGER_AVAILABLE